Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 4:41 p.m.

    📋 Ultragenyx Pharmaceutical Inc. (RARE) - Financial Results

    Filing Date: 2022-07-28

    Accepted: 2022-07-28 16:09:26

    Event Type: Financial Results

    Event Details:

    Ultragenyx Pharmaceutical Inc (RARE) Reports Q3 2022 Financial Results Ultragenyx Pharmaceutical Inc (RARE) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 8270
    • Net Income: Not disclosed
    • EPS: 4933
    • Cash and equivalents: 706096
      • expected in the second half of 2022
      • anticipated in second half of 2022

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Operating Expense Selling General Administrative 53.41K 135.45K $-82.04K -60.57%
    Operating Expense Net Loss 122.43K 310.48K $-188.05K -60.57%
    Operating Expense Net Loss Per Share 1.81 4.45 $-2.64 -59.33%
    Operating Expenses Selling General Administrative 53.41K 135.45K $-82.04K -60.57%
    Operating Expenses Loss From Operations 82.78K 278.23K $-195.45K -70.25%
    Operating Expenses Total Other Income Expense 374.00 752.00 $-378.00 -50.27%
    Operating Expenses Net Loss 122.43K 310.48K $-188.05K -60.57%
    Operating Expenses Net Loss Per Share 1.81 4.45 $-2.64 -59.33%
    Operating Expenses Weighted Average Shares 67.61M 69.72M $-2.11M -3.03%
    Balance Sheet Data Cash Equivalents Marketable Securities 706.10K 999.13K $-293.03K -29.33%
    Revenue 5.42K 4.92K $506.00 +10.29%
    Selling, General & Administrative 68.14K 53.41K $14.73K +27.57%
    Net Loss 158.16K 122.43K $35.73K +29.19%
    Loss from Operations 141.59K 82.78K $58.82K +71.06%
    Interest Expense 6.05K 8.52K $-2.46K -28.94%

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Ultragenyx Pharmaceutical Inc
    • CIK: 0001515673
    • Ticker Symbol: RARE
    • Period End Date: 2022-07-28
    • Document Type: 8-K

Search

News categories